Evidence method
Level · gp.fundamentals.capex_revenue_ratio
1.96% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CTKB · Sep 30, 2024
Cytek Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-24-045834General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
25.67% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
7.29% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
90.87% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
56.32% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-8.25% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
19.19% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
13.70% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History21 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/8 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20235/8 normalizedLevel 3Sep 30, 20237/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 2.26%
- Current
- 1.96%
- Delta
- -0.30%
- Previous
- 13.31%
- Current
- 25.67%
- Delta
- 12.36%
- Previous
- -6.19%
- Current
- 7.29%
- Delta
- 13.48%
- Previous
- 107.41%
- Current
- 90.87%
- Delta
- -16.53%
- Previous
- 54.56%
- Current
- 56.32%
- Delta
- 1.76%
- Previous
- -18.29%
- Current
- -8.25%
- Delta
- 10.04%
- Previous
- 21.45%
- Current
- 19.19%
- Delta
- -2.27%
- Previous
- 15.34%
- Current
- 13.70%
- Delta
- -1.65%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CTKB Fundamental State →Analogous To · CTKB state analogue 4 →Transitioned To · CTKB Fundamental State →Transitioned To · CTKB CAPEX_INTENSITY_DECREASED →Transitioned To · CTKB CASH_GENERATION_INCREASED →Transitioned To · CTKB GROWTH_INCREASED →Transitioned To · CTKB INVENTORY_PRESSURE_DECREASED →Transitioned To · CTKB MARGIN_INCREASED →Transitioned To · CTKB PROFITABILITY_INCREASED →Transitioned To · CTKB R_AND_D_INTENSITY_DECREASED →Transitioned To · CTKB SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.